This study assesses healthcare providers' awareness, usage, and perceptions of GLP-1 therapies for type 2 diabetes and weight management. It explores the clinical, logistical, and economic factors that influence their prescribing decisions.
75% of HCPs associate Ozempic with superior CV benefits vs. 46% for Mounjaro, with 62% of Ozempic prescribing decisions citing cardiovascular benefits compared to 41% for Mounjaro.
Strong weight loss efficacy association for Zepbound influences HCP perceptions of tirzepatide overall, with 85% viewing Mounjaro's weight loss benefits favorably vs. 75% for Ozempic in T2D decisions.
While HCPs report minimal coverage differences across GLP-1s, cost and coverage restrictions affect 75-78% of prescribing decisions with challenges more pronounced for tirzepatide products in the weight loss setting.
Semaglutide (Ozempic/Wegovy) is currently favored over Tirzepatide (Mounjaro/Zepbound) in HCP decision-making when cardiovascular benefit is a priority, reinforcing its role as a leading driver of GLP-1 selection in both T2D and weight loss.
Among HCPs Semaglutide (Ozempic/Wegovy) is more closely linked to cardiovascular benefit than Tirzepatide (Mounjaro/Zepbound), suggesting stronger brand recognition for heart-related outcomes across both indications
Strong brand association with weight loss efficacy for Zepbound is influencing HCP perceptions of Tirzepatide overall, positioning Mounjaro as a compelling option even in T2D care
Prescribing is rarely driven by access, but favorable coverage for Semaglutide gives Ozempic and Wegovy a modest edge over Tirzepatide competitors
Cost and coverage restrictions are the leading barriers to GLP-1 prescribing, with challenges especially pronounced in the weight loss setting and more acute for Tirzepatide products
Ozempic and Wegovy lead on access and affordability brand associations, though overall perceptions remain modest across GLP-1 brands
HCPs weigh both glycemic control and weight loss benefits heavily when selecting treatments, with weight loss emerging as a critical driver across both T2D and weight loss contexts
While tirzepatide and semaglutide dominate NASH recognition at ~67% each, CagriSema leads next-generation awareness in diabetes and weight loss at ~50%. Significant knowledge gaps persist with >50% HCPs unaware of pipeline options across key metabolic indications.
ZoomRx offers a wide range of AI-driven MR tools to empower your team to push beyond boundaries.
LEARN MORE